Kwekkeboom D J, Krenning E P
Department of Nuclear Medicine, University Hospital Rotterdam, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.
Eur Radiol. 1997;7(7):1103-9. doi: 10.1007/s003300050262.
[111In-DTPA-D-Phe1]-octreotide is a new radiopharmaceutical with a great potential for the visualization of somatostatin receptor-positive tumors, granulomas, and diseases in which activated leukocytes play a role. The overall sensitivity of [111In-DTPA-D-Phe1]-octreotide scintigraphy to localize neuroendocrine tumors is high. In several neuroendocrine tumor types, inclusion of somatostatin receptor imaging in the localization or staging procedure may be very rewarding, either in terms of cost-effectiveness, patient management, or quality of life. In our opinion, this holds true for patients with carcinoids, gastrinomas, paragangliomas, small-cell lung carcinoma, and selected cases of patients with insulinomas. The value of [111In-DTPA-D-Phe1]-octreotide scintigraphy in patients with other tumors, such as breast cancer, malignant lymphomas, or in patients with granulomatous diseases, has to be established.
[111铟-二乙三胺五乙酸-D-苯丙氨酸1]-奥曲肽是一种新型放射性药物，在可视化生长抑素受体阳性肿瘤、肉芽肿以及活化白细胞起作用的疾病方面具有巨大潜力。[111铟-二乙三胺五乙酸-D-苯丙氨酸1]-奥曲肽闪烁扫描术定位神经内分泌肿瘤的总体敏感性较高。在几种神经内分泌肿瘤类型中，无论是从成本效益、患者管理还是生活质量方面考虑，在定位或分期程序中纳入生长抑素受体成像可能都非常有益。我们认为，这适用于类癌、胃泌素瘤、副神经节瘤、小细胞肺癌患者以及部分胰岛素瘤患者。[111铟-二乙三胺五乙酸-D-苯丙氨酸1]-奥曲肽闪烁扫描术在其他肿瘤患者（如乳腺癌、恶性淋巴瘤患者）或肉芽肿性疾病患者中的价值还有待确定。
